Centers for Disease Control and Prevention (CDC)'ss Advisory Committee On Immunization Practices Recommends Pfizer Inc.'s Prevnar 13(TM) Vaccine For The Prevention Of Invasive Pneumococcal Disease In Infants And Young Children In The U.S.

NEW YORK--(BUSINESS WIRE)--Pfizer Inc (NYSE:PFE) announced today that the United States Centers for Disease Control and Prevention’s (CDC’s) Advisory Committee on Immunization Practices (ACIP) has recommended the use of Prevnar 13™ (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) for healthy children aged 2 months through 59 months for the prevention of invasive pneumococcal disease caused by the 13 pneumococcal serotypes included in the vaccine.